SOUTH SAN FRANCISCO, Calif., March 25, 2026
In a landmark regulatory milestone, Denali Therapeutics announced that the U.S. Food and Drug Administration has granted accelerated approval to AVLAYAH™ (tividenofusp alfa-eknm), marking the first new treatment option in nearly 20 years for patients suffering from Hunter syndrome (MPS II). This approval is particularly significant as AVLAYAH represents a first-in-class biologic engineered to cross the blood-brain barrier, directly addressing the neurological complications of this rare genetic disorder. Hunter syndrome, a lysosomal storage disease, leads to the accumulation of glycosaminoglycans (GAGs), causing progressive damage to multiple organs including the brain, and until now, treatment options have been limited in addressing central nervous system involvement.
Breakthrough Mechanism and Clinical Impact
AVLAYAH introduces a novel therapeutic approach leveraging Denali’s proprietary TransportVehicle™ platform, enabling targeted delivery of enzyme replacement therapy across the blood-brain barrier, a longstanding challenge in drug development. The therapy is specifically designed to deliver the deficient iduronate 2-sulfatase (IDS) enzyme to both peripheral tissues and the brain. Clinical data supporting approval demonstrated a remarkable 91% reduction in cerebrospinal fluid heparan sulfate (CSF HS) levels within 24 weeks, a key biomarker associated with disease progression. Notably, 93% of treated patients achieved near-normal biomarker levels, reinforcing the drug’s potential to significantly alter disease trajectory. The approval was granted under the FDA’s accelerated pathway, relying on biomarker reduction as a surrogate endpoint, with ongoing Phase 2/3 COMPASS trials expected to confirm long-term clinical benefits.
Transforming Rare Disease Treatment Landscape
This approval is being widely recognized as a major advancement in rare disease therapeutics, particularly for conditions involving neurological decline. AVLAYAH is the first FDA-approved therapy capable of addressing both systemic and neurological manifestations of Hunter syndrome, potentially establishing a new standard of care. The therapy is indicated for pediatric patients weighing at least 5 kg, ideally before advanced neurological damage occurs, emphasizing the importance of early diagnosis and intervention. In addition to its clinical significance, the FDA has awarded Denali a Rare Pediatric Disease Priority Review Voucher (PRV), which can expedite future drug reviews or be monetized, highlighting the strategic and commercial value of this approval. The drug will be administered via weekly intravenous infusion, with support programs planned to assist patients and caregivers in treatment access and adherence
Advertisement
Industry and Regulatory Implications
The approval of AVLAYAH underscores a paradigm shift in biologics development, particularly in overcoming the blood-brain barrier limitation, which has historically restricted therapeutic innovation in neurological diseases. Denali’s TransportVehicle™ platform has now achieved clinical validation, opening doors for broader applications across neurodegenerative disorders, lysosomal storage diseases, and other CNS-related conditions. From a regulatory standpoint, this decision also reinforces the FDA’s willingness to leverage biomarker-driven approvals in areas of high unmet medical need, potentially accelerating future drug development timelines. However, it is critical to note that continued approval remains contingent on confirmatory trial outcomes, and safety considerations such as infusion-related reactions and hypersensitivity risks will require careful clinical management.
The FDA approval of AVLAYAH represents a defining moment in precision biologics and rare disease treatment, combining innovative drug delivery technology with strong clinical efficacy signals. This therapy introduces a first-in-class approach capable of crossing the blood-brain barrier, directly targeting neurological manifestations that were previously untreated in Hunter syndrome. Despite the need for further confirmatory clinical data to validate long-term outcomes, AVLAYAH already demonstrates the potential to reshape treatment strategies for CNS-related rare diseases and establishes a new benchmark for next-generation biologics development in the pharmaceutical industry.
Source: Denali Therapeutics press release
